ES2962865T3 - Nuevos derivados de azetidina útiles como moduladores de la neurotransmisión catecolaminérgica cortical - Google Patents
Nuevos derivados de azetidina útiles como moduladores de la neurotransmisión catecolaminérgica cortical Download PDFInfo
- Publication number
- ES2962865T3 ES2962865T3 ES17807779T ES17807779T ES2962865T3 ES 2962865 T3 ES2962865 T3 ES 2962865T3 ES 17807779 T ES17807779 T ES 17807779T ES 17807779 T ES17807779 T ES 17807779T ES 2962865 T3 ES2962865 T3 ES 2962865T3
- Authority
- ES
- Spain
- Prior art keywords
- azetidine
- difluorophenoxy
- compound
- trifluorophenoxy
- phenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16199545 | 2016-11-18 | ||
| PCT/EP2017/079666 WO2018091687A1 (en) | 2016-11-18 | 2017-11-17 | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2962865T3 true ES2962865T3 (es) | 2024-03-21 |
Family
ID=57348567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17807779T Active ES2962865T3 (es) | 2016-11-18 | 2017-11-17 | Nuevos derivados de azetidina útiles como moduladores de la neurotransmisión catecolaminérgica cortical |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10875829B1 (enExample) |
| EP (1) | EP3541784B1 (enExample) |
| JP (1) | JP6990702B2 (enExample) |
| CN (1) | CN109963834B (enExample) |
| DK (1) | DK3541784T5 (enExample) |
| ES (1) | ES2962865T3 (enExample) |
| FI (1) | FI3541784T3 (enExample) |
| PL (1) | PL3541784T3 (enExample) |
| PT (1) | PT3541784T (enExample) |
| WO (1) | WO2018091687A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112198237B (zh) * | 2020-05-28 | 2021-08-06 | 扬子江药业集团广州海瑞药业有限公司 | 一种盐酸奈康唑杂质检测控制分析方法 |
| WO2025008506A1 (en) | 2023-07-06 | 2025-01-09 | Integrative Research Laboratories Sweden Ab | 3-(2,3-difluorophenoxy)azetidine, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of pathological apathy |
| AU2024289298A1 (en) | 2023-07-06 | 2026-01-15 | Integrative Research Laboratories Sweden Ab | Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070021404A1 (en) | 2003-06-24 | 2007-01-25 | Dan Peters | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
| WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| EP2367787B1 (en) | 2008-11-24 | 2013-01-09 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission |
| JP5621087B2 (ja) * | 2008-11-24 | 2014-11-05 | インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー | 皮質のカテコールアミン作動性神経伝達のモジュレーターとして有用な新規な３−フェニル−アゼチジン誘導体 |
| WO2010084428A1 (en) | 2009-01-20 | 2010-07-29 | Pfizer Inc. | Substituted pyrazinone amides |
| TWI404721B (zh) * | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| JP2013519732A (ja) * | 2010-02-17 | 2013-05-30 | アムジエン・インコーポレーテツド | 疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体 |
| EP2718295A1 (en) | 2011-06-07 | 2014-04-16 | Pfizer Inc | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
| KR101273566B1 (ko) | 2011-09-05 | 2013-06-11 | 한국과학기술연구원 | 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물 |
| AP2014007820A0 (en) * | 2012-01-26 | 2014-07-31 | Lundbeck & Co As H | PDE9 inhibitors with imidazo triazinone backbone |
| BR112017000160A2 (pt) | 2014-08-27 | 2017-10-31 | Hoffmann La Roche | derivados de azetidina substituidos como ligantes de taar |
| TWI601712B (zh) * | 2014-11-05 | 2017-10-11 | 達特神經科學（開曼）有限責任公司 | 作為ｇｌｙｔ１抑制劑之經取代之氮雜環丁基化合物 |
| AU2016263510B2 (en) * | 2015-05-20 | 2020-03-12 | Integrative Research Laboratories Sweden Ab | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
| WO2017045648A1 (zh) | 2015-09-18 | 2017-03-23 | 正大天晴药业集团股份有限公司 | 一种氘代化合物的制备方法 |
| JOP20190077A1 (ar) * | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
-
2017
- 2017-11-17 PL PL17807779.8T patent/PL3541784T3/pl unknown
- 2017-11-17 EP EP17807779.8A patent/EP3541784B1/en active Active
- 2017-11-17 PT PT178077798T patent/PT3541784T/pt unknown
- 2017-11-17 ES ES17807779T patent/ES2962865T3/es active Active
- 2017-11-17 WO PCT/EP2017/079666 patent/WO2018091687A1/en not_active Ceased
- 2017-11-17 FI FIEP17807779.8T patent/FI3541784T3/fi active
- 2017-11-17 CN CN201780069687.6A patent/CN109963834B/zh active Active
- 2017-11-17 JP JP2019525851A patent/JP6990702B2/ja active Active
- 2017-11-17 US US16/461,086 patent/US10875829B1/en active Active
- 2017-11-17 DK DK17807779.8T patent/DK3541784T5/da active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019535715A (ja) | 2019-12-12 |
| EP3541784A1 (en) | 2019-09-25 |
| DK3541784T3 (en) | 2023-10-23 |
| DK3541784T5 (da) | 2024-09-16 |
| CN109963834A (zh) | 2019-07-02 |
| PT3541784T (pt) | 2023-11-22 |
| PL3541784T3 (pl) | 2024-03-11 |
| FI3541784T3 (fi) | 2023-10-02 |
| CN109963834B (zh) | 2023-04-14 |
| EP3541784B1 (en) | 2023-09-13 |
| US10875829B1 (en) | 2020-12-29 |
| WO2018091687A1 (en) | 2018-05-24 |
| JP6990702B2 (ja) | 2022-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2962865T3 (es) | Nuevos derivados de azetidina útiles como moduladores de la neurotransmisión catecolaminérgica cortical | |
| JP5716202B2 (ja) | 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての３−フェニル−３−メトキシピロリジン誘導体 | |
| US20250042905A1 (en) | Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis | |
| US10287247B2 (en) | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | |
| JP5870031B2 (ja) | 自動化放射合成 | |
| WO2025037013A1 (en) | Diagnostic compounds that bind to alpha-synuclein | |
| HK1245251A1 (en) | Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | |
| CN118027016A (zh) | Parg抑制剂及其制备方法和用途 | |
| TW201245197A (en) | Substituted [(5h-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists | |
| MX2011005034A (es) | Nuevos derivados de 3-fenil-azetidina utiles como moduladores de la neurotransmision catecolaminergica cortical. | |
| US12281116B2 (en) | HTT modulators for treating Huntington's disease | |
| HK40092922A (en) | Vmat2 inhibitors and methods of use | |
| HK40092922B (en) | Vmat2 inhibitors and methods of use | |
| CN113727713A (zh) | 氟取代的2-氨基噻唑-5-芳香族甲酰胺的用途 |